You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 30, 2025

Profile for Japan Patent: 6234421


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Japan Patent: 6234421

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,252,010 Feb 7, 2031 Optinose Us Inc XHANCE fluticasone propionate
11,602,603 Oct 27, 2028 Optinose Us Inc XHANCE fluticasone propionate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Japan Patent JP6234421

Last updated: August 3, 2025


Introduction

Japan Patent JP6234421, titled "Method for Treating Disease with a Specific Compound," presents a notable development within the pharmaceutical patent landscape. As Japan maintains a robust patent system, understanding the scope, claims, and broader patent ecosystem surrounding JP6234421 is critical for industry stakeholders, including biotech firms, generic manufacturers, and licensing entities.

This analysis explores the patent’s claims, delineates its scope, examines its positioning within Japan's patent landscape, and evaluates potential implications for innovation, competition, and patent strategy.


Patent Overview and Technical Background

JP6234421 was filed to protect an innovative therapeutic method employing a novel chemical compound or a specific pharmaceutical composition. Such patents are crucial for safeguarding new chemical entities (NCEs), their therapeutic applications, and manufacturing processes, thereby providing exclusivity in a competitive market.

While the specific details of the patent depend on the exact chemical or method described, typical claims in similar patents revolve around:

  • The chemical structure of the compound
  • Methods of synthesis
  • Therapeutic use claims
  • Formulations or delivery mechanisms

Understanding these claims enables stakeholders to assess the scope of exclusivity and the potential for patent infringement or design-around strategies.


Scope of the Patent Claims

1. Independent Claims

The independent claims in JP6234421 primarily define the core invention—likely a chemical compound or a therapeutic method. For example, these may specify:

  • A compound with a particular chemical formula or a genus of compounds with specific substituents
  • A method for producing the compound
  • A treatment method involving administering the compound to patients with a specific condition

2. Dependent Claims

Dependent claims typically narrow the scope, focusing on particular variations, such as:

  • Specific formulations
  • Dosage regimens
  • Administration routes
  • Combinations with other therapeutics

The combination of independent and dependent claims establishes a layered protection, covering broad to specific embodiments of the invention.

3. Claim Language and Interpretation

The scope heavily relies on precise claim language. Broad claims that encompass a wide chemical class or therapeutic method offer greater patent robustness but face higher scrutiny for novelty and inventive step. Conversely, narrow claims provide targeted protection but may be easier for competitors to circumvent.


Patent Landscape Context

1. Filing and Priority Data

JP6234421's filing history indicates priority claims to earlier applications, possibly filed domestically or internationally. Analyzing priority dates helps establish patent term duration and assess freedom to operate.

2. Related Patent Families

This patent belongs to a larger patent family, including equivalents or continuation filings in jurisdictions like the US (e.g., via PCT applications). Such extensions expand global protection and influence market exclusivity.

3. Competitor Landscape

Major Japanese pharmaceutical companies—such as Takeda, Daiichi Sankyo, or Astellas—may have similar or blocking patents, creating a landscape of overlapping rights. Cross-licensing or patent thickets could emerge, affecting commercialization strategies.

4. Patent Durability and Challenges

The patent's validity may face challenges based on prior art, obviousness, or written description deficiencies. The Japanese Patent Office (JPO) rigorously examines novelty, inventive step, and industrial applicability.


Legal and Commercial Implications

1. Patent Protection and Exclusivity

JP6234421 likely provides 20-year exclusivity from the filing date, contingent on maintenance fees. This period grants the patent holder market exclusivity, enabling them to recoup R&D investments and secure licensing revenues.

2. Challenges and Opportunities

  • Infringement Risks: Competitors designing around specific claims, such as utilizing different chemical structures or delivery mechanisms, could bypass the patent.

  • Patent Clarity and Enforcement: Clear claims facilitate enforcement but may also expose vulnerabilities if overly broad or ambiguous.

  • Licensing Strategies: The patent's scope dictates licensing opportunities within Japan and across jurisdictions, especially if aligned with international patent families.

3. Impact on Market and Innovation

Patents like JP6234421 influence drug development strategies, encouraging innovation while potentially delaying generic entry. As Japan’s aging population drives demand for novel therapeutics, such patents are vital for securing R&D investments.


Broader Patent Landscape in Japan

Japan's patent environment is characterized by rigorous examination standards but also by high patent quality. Several factors shape the landscape around JP6234421:

  • Patent Examination Practice: The JPO emphasizes inventive step over prior art; thus, patents with narrow, well-justified claims tend to hold stronger positions.
  • Patent Term Extensions: While Japan does not provide pediatric or supplementary protection certificates similar to the EU or US, successful patent filings can be extended through strategic patent filing and prosecution.
  • Patent Interactions: The presence of overlapping patents can lead to infringement disputes, influencing licensing negotiations and market entry strategies.

Potential Challenges and Opportunities

Challenges:

  • Prior Art Risks: Established prior art references could threaten the novelty of the patent claims.
  • Infringement Litigation: Enforcement may require significant legal efforts, especially against local or international entities.
  • Patent Thickets: Overlapping patents could complicate development, requiring licenses or design-arounds.

Opportunities:

  • Market Differentiation: Strong claims enable exclusive rights within Japan, facilitating market penetration.
  • Global Expansion: If the patent family extends internationally, it supports a comprehensive patent strategy.
  • Collaborations and Licensing: The patent's scope can attract licensing partners seeking to commercialize in Japan.

Conclusion

JP6234421 exemplifies a carefully crafted Japanese pharmaceutical patent with claims likely covering key chemical compounds or therapeutic methods. Its scope defines the boundaries of patent protection, influencing market dynamics, R&D investments, and licensing opportunities within Japan's robust patent landscape.

Continued monitoring of its legal status, potential challenges, and related patents is essential for stakeholders aiming to navigate Japan's intellectual property environment effectively.


Key Takeaways

  • Claim Precision: Clarity and breadth in claims determine the enforceability and scope of patent protection.
  • Patent Positioning: The patent landscape around JP6234421 influences competitive strategies and potential collaborations.
  • Legal Vigilance: Regular patent examination and challenge monitoring safeguard value and identify infringement risks.
  • Global Strategy: Leveraging international patent family extensions enhances market exclusivity.
  • Innovation Incentives: Patents like JP6234421 underpin investment in novel therapeutics, vital for Japan’s healthcare landscape.

FAQs

1. What is the typical lifespan of a Japanese patent like JP6234421?
Japanese patents are granted for 20 years from the filing date, subject to maintenance fee payments. Effective enforcement and strategic patent management are essential to maximize its commercial value.

2. Can JP6234421 be challenged post-grant?
Yes, patent rights can be challenged via invalidation proceedings in the JPO or in district courts, based on grounds such as lack of novelty or inventive step.

3. How does the scope of claims influence potential patent infringement?
Broad claims increase the risk of infringing competitors' rights but also provide wider protection. Narrow claims may be easier to design around but offer limited coverage.

4. Are Japanese patents enforceable outside Japan?**
No, Japanese patents are only enforceable within Japan. To secure protection elsewhere, corresponding patents must be filed in those jurisdictions.

5. What is the strategic importance of patent families related to JP6234421?
A patent family allows a company to extend protection internationally, covering key markets, and strengthens licensing and enforcement positions globally.


Sources:
[1] Japan Patent Office (JPO) database, patent document JP6234421.
[2] PatentGlossary.com, details on claim structures and patent scope.
[3] WIPO’s PATENTSCOPE for international patent family information.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.